top of page
Search

First New Zealand Registration of Guideline Recommended UTI Treatment

Writer: scottlissingtonscottlissington

The Prescription Medicine UroFos® (fosfomycin) has been registered by Medsafe for the treatment of acute uncomplicated urinary tract infection (UTIs) in adult women and adolescents aged over 12.

"UroFos® represents the first of a new antibiotic class in New Zealand and is registered as a single dose treatment for women experiencing a UTI. Single dose oral fosfomycin is convenient and highly effective against a broad range of UTI causing bacteria, these advantages are reflected in PHARMACs high priority recommendation for funding.” Scott Lissington COO Te Arai BioFarma.

For more information:

Te Arai BioFarma Ltd. 0800 TE ARAI.

UroFos® (Fosfomycin) is a Prescription Medicine. For full information please consult the Medsafe website and product data sheet at www.medsafe.govt.nz. UroFos® is a registered Trademark of Te Arai BioFarma Ltd, Auckland.

Te Arai BioFarma is a New Zealand owned family company created to improve access to Medicines for New Zealanders

 
 
 

Komentarze


Te Arai Biopharma logo Med Frame.png

PO Box 46205,
Herne Bay 1147,
Auckland, New Zealand

0800 832 724

Home

News

Contact Us

Copyright © 2013 TeArai BioFarma Limited.

bottom of page